Nachrichten zur Cardiff Oncology Aktie

By John Vandermosten, CFA NASDAQ:CRDFREAD THE FULL CRDF RESEARCH REPORTWe are initiating coverage of Cardiff Oncology, Inc.…

…

…

Cardiff Oncology shares plunge after Q2 earnings miss…

Cardiff Oncology (CRDF) delivered earnings and revenue surprises of -10.53% and -19.33%, respectively, for the quarter ended June 2025. Do…

Cardiff Oncology (CRDF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to…

…

…

Cardiff Oncology (CRDF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming…

Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 16% and 11.85%, respectively, for the quarter ended December 2024. Do…

…

…

Cardiff Oncology Inc. (CRDF) ist ein Biotech mit Fokus auf die Behandlung von Krebserkrankungen. PLK1 (Polo-like kinase 1) ist ein…

…

Cardiff Oncology stock rallies as initial data from a phase II study of onvansertib shows superior efficacy over SOC chemotherapy…

…

…

…

…

…

…

…

Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 19.23% and 108%, respectively, for the quarter ended December 2023. Do…